Article Text

Download PDFPDF
Ovarian Yolk Sac Tumor: The Experience of a Regional Cancer Center
  1. Xiaojing Wang, MD,
  2. Zebiao Ma, MD and
  3. Yanfang Li, MD
  1. * Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou; and
  2. Department of Gynecologic Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Henan Province Cancer Hospital, Zhengzhou, Henan, People’s Republic of China.
  1. Address correspondence and reprint requests to Yanfang Li, MD, Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Rd E, Guangzhou, People’s Republic of China 510060. E-mail: liyf{at}sysucc.org.cn.

Abstract

Objective The aim of this study was to evaluate the clinicopathologic characteristics of patients with ovarian yolk sac tumor and the benefit of omentectomy in patients with clinical early-stage disease.

Methods The medical records of 66 patients with ovarian yolk sac tumor were reviewed retrospectively.

Results There were 37, 8, 14, and 7 patients with stages I, II, III, and IV disease, respectively. Sixty-five patients received surgery and adjuvant chemotherapy, and 1 had chemotherapy only. The median follow-up was 78 months. The overall 5-year survival rate was 86.0%. Univariate analysis revealed that stage (P = 0 .022), age (P = 0.001), residual tumor (P = 0.036), and satisfactory α-fetoprotein (AFP) decline (defined as normalization of AFP after the first or second cycles of postsurgery chemotherapy, P = 0.006) were significant prognostic factors. Multivariate analysis revealed that satisfactory AFP decline was an independent significant prognostic factor for overall survival (P = 0.028). The postoperative pathology showed that only 1 (2.7%) of 37 patients who received omentectomy without gross spread had omentum metastasis microscopically. The 5-year survival rates were 89.2% and 100.0% for stage I-II patients with (36 cases) or without (9 cases) omentectomy, respectively (P > 0.05). Three of the 7 patients with recurrence were successfully salvaged and lived 38.0, 102.6, and 45.2 months after initial diagnosis.

Conclusions Postsurgery satisfactory AFP decline was an independent significant prognostic factor for patient survival. Omentectomy might not be of therapeutic significance for clinical stage I-II patients.

  • AFP decline
  • Chemotherapy
  • Omentectomy
  • Ovarian yolk sac tumor

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.